Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC Meeting Abstract
| Authors: | Hellmann, M.; Cho, B.; Juergens, R.; Cheng, Y.; de Castro, G.; Erman, M.; Bauman, J.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; Pietanza, M. C.; Yang, J. C. H. |
| Abstract Title: | Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC |
| Meeting Title: | 36th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2021) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 9 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Nov 10-14 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2021-11-01 |
| Start Page: | A488 |
| Language: | English |
| ACCESSION: | WOS:000774877500441 |
| DOI: | 10.1136/jitc-2021-SITC2021.459 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 459 -- Meeting was also held virtually -- Source: Wos |
